AGENUS INC Other Noncash Income (Expense)
AGENUS INC (AGEN) reported Other Noncash Income (Expense) of -$1.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-07
- AGENUS INC other noncash income (expense) for the quarter ending 2026-06-30 was -$1.27M.
- AGENUS INC other noncash income (expense) for the quarter ending 2026-03-31 was -$428.00K, a 2240.00% decline year-over-year.
- AGENUS INC other noncash income (expense) for the quarter ending 2025-12-31 was -$3.15M.
- AGENUS INC other noncash income (expense) for the quarter ending 2025-09-30 was $409.00K, a 91.47% decline year-over-year.
- AGENUS INC other noncash income (expense) for fiscal 2025 was -$2.95M, a 3382.22% decline from fiscal 2024.
- AGENUS INC other noncash income (expense) for fiscal 2024 was $90.00K, a 24.37% decline from fiscal 2023.
- AGENUS INC other noncash income (expense) for fiscal 2023 was $119.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$1.70M 10-Q · filed 2026-08-07 | -$4.86M derived: sum of 3 quarters · filed 2026-08-07 | -$4.45M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | -$428.00K 10-Q · filed 2026-05-11 | -$3.58M derived: sum of 2 quarters · filed 2026-05-11 | -$3.17M derived: sum of 3 quarters · filed 2026-05-11 | -$3.40M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$2.75M derived: sum of 2 quarters · filed 2026-03-16 | -$2.97M derived: sum of 3 quarters · filed 2026-08-07 | -$2.95M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $409.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $180.00K derived: sum of 2 quarters · filed 2026-08-07 | $200.00K 10-Q · filed 2025-11-10 | -$3.45M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | -$229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$209.00K 10-Q · filed 2026-08-07 | -$255.00K 10-Q · filed 2025-08-11 | -$3.86M derived: sum of 3 quarters · filed 2026-08-07 | $937.00K derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $20.00K 10-Q · filed 2026-05-11 | -$73.00K 10-Q · filed 2025-05-12 | -$3.63M derived: sum of 2 quarters · filed 2026-05-11 | $1.17M derived: sum of 3 quarters · filed 2026-05-11 | $1.24M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | -$3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.15M derived: sum of 2 quarters · filed 2026-03-16 | $1.22M derived: sum of 3 quarters · filed 2026-03-16 | $90.00K 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.88M derived: sum of 2 quarters · filed 2025-11-10 | $3.74M 10-Q · filed 2025-11-10 | $2.64M 10-Q · filed 2024-11-12 | $4.04M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.06M 10-Q · filed 2025-08-11 | -$754.00K derived: sum of 3 quarters · filed 2026-03-16 | -$1.09M derived: sum of 4 quarters · filed 2026-03-16 | |||
| 2024-03-31 | -$1.13M 10-Q · filed 2025-05-12 | -$1.13M 10-Q · filed 2024-05-07 | -$832.00K derived: sum of 2 quarters · filed 2026-03-16 | -$1.16M derived: sum of 3 quarters · filed 2026-03-16 | -$1.42M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2023-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$30.00K derived: sum of 2 quarters · filed 2026-03-16 | -$287.00K derived: sum of 3 quarters · filed 2026-03-16 | $119.00K 10-K · filed 2026-03-16 | |||
| 2023-09-30 | -$332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$589.00K derived: sum of 2 quarters · filed 2024-11-12 | -$183.00K 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $149.00K 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | $406.00K 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |